
Gilbert Donders

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2342148/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aerobic Vaginitis Diagnosis Criteria Combining Gram Stain with Clinical Features: An Establishment and Prospective Validation Study. Diagnostics, 2022, 12, 185.	2.6	8
2	Lab-Based Retrospective 10-Year Analysis Shows Seasonal Variation of Vaginal Candida Infection Rates in Belgium. Journal of Clinical Medicine, 2022, 11, 574.	2.4	2
3	Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test. Fertility and Sterility, 2022, 117, 287-296.	1.0	76
4	Long Term Outcome of Surgical Treatment of Central Introital Dyspareunia. Journal of Clinical Medicine, 2022, 11, 2066.	2.4	1
5	Literature Review of Cervical Regeneration after Loop Electrosurgical Excision Procedure, and Study Project (CeVaLEP) Proposal. Journal of Clinical Medicine, 2022, 11, 2096.	2.4	1
6	Association between maternal cervicovaginal swab positivity for Ureaplasma spp. or other microorganisms and neonatal respiratory outcome and mortality. Journal of Perinatology, 2021, 41, 1-11.	2.0	3
7	Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis. Cellular and Molecular Life Sciences, 2021, 78, 1191-1206.	5.4	27
8	Aerobic Vaginitis—Underestimated Risk Factor for Cervical Intraepithelial Neoplasia. Diagnostics, 2021, 11, 97.	2.6	21
9	Negative Impact of Elevated DNA Fragmentation and Human Papillomavirus (HPV) Presence in Sperm on the Outcome of Intra-Uterine Insemination (IUI). Journal of Clinical Medicine, 2021, 10, 717.	2.4	9
10	Genital Tract GAS Infection ISIDOG Guidelines. Journal of Clinical Medicine, 2021, 10, 2043.	2.4	12
11	ISIDOG Consensus Guidelines on COVID-19 Vaccination for Women before, during and after Pregnancy. Journal of Clinical Medicine, 2021, 10, 2902.	2.4	18
12	Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study. Archives of Public Health, 2021, 79, 155.	2.4	21
13	Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. Gynecologic Oncology, 2021, 162, 575-583.	1.4	27
14	Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 245, 13-18.	1.1	21
15	The Correlation Between Abnormal Uterine Artery Flow in the First Trimester and Genetic Thrombophilic Alteration: A Prospective Case-Controlled Pilot Study. Diagnostics, 2020, 10, 654.	2.6	1
16	The Dwindling Microbiota of Aerobic Vaginitis, an Inflammatory State Enriched in Pathobionts with Limited TLR Stimulation. Diagnostics, 2020, 10, 879.	2.6	19
17	The use of 3 selected lactobacillary strains in vaginal probiotic gel for the treatment of acute Candida vaginitis: a proof-of-concept study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1551-1558.	2.9	9
18	Impact of a lactobacilli-containing gel on vulvovaginal candidosis and the vaginal microbiome. Scientific Reports, 2020, 10, 7976.	3.3	25

#	Article	IF	CITATIONS
19	Vaginal pH and microbiota during fluconazole maintenance treatment for recurrent vulvovaginal candidosis (RVVC). Diagnostic Microbiology and Infectious Disease, 2020, 97, 115024.	1.8	9
20	ISIDOG Recommendations Concerning COVID-19 and Pregnancy. Diagnostics, 2020, 10, 243.	2.6	71
21	Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5893-5905.	3.6	62
22	Univariate Statistical Analysis as a Guide to 1H-NMR Spectra Signal Assignment by Visual Inspection. Metabolites, 2019, 9, 15.	2.9	11
23	Development and validation of a new one step Multiplex-PCR assay for the detection of ten Lactobacillus species. Anaerobe, 2019, 59, 192-200.	2.1	6
24	Pharmacotherapy for the treatment of vaginal atrophy. Expert Opinion on Pharmacotherapy, 2019, 20, 821-835.	1.8	38
25	The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5†years of follow-up. Gynecologic Oncology, 2019, 153, 521-529.	1.4	43
26	Treatment Attitudes for Belgian Women With Persistent Trichomonas vaginalis Infection in the VlaResT Study. Clinical Infectious Diseases, 2019, 68, 1575-1580.	5.8	2
27	Prevalence of Ureaplasma spp. and Mycoplasma hominis in healthy women and patients with flora alterations. Diagnostic Microbiology and Infectious Disease, 2019, 93, 227-231.	1.8	39
28	ls nonâ€response to fluconazole maintenance therapy for recurrent <i>Candida</i> vaginitis related to sensitization to atopic reactions?. American Journal of Reproductive Immunology, 2018, 79, e12811.	1.2	15
29	Diagnosis and management of vulvodynia in postmenopausal women. Maturitas, 2018, 108, 84-94.	2.4	21
30	Anti-Candida activity of antidepressants sertraline and fluoxetine: effect upon pre-formed biofilms. Medical Microbiology and Immunology, 2018, 207, 195-200.	4.8	26
31	VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. Journal of Clinical Virology, 2018, 107, 52-56.	3.1	72
32	Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. Journal of Infection, 2018, 76, 449-456.	3.3	22
33	Abnormal vaginal microbioma is associated with severity of localized provoked vulvodynia. Role of aerobic vaginitis and Candida in the pathogenesis of vulvodynia. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1679-1685.	2.9	18
34	2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. International Journal of STD and AIDS, 2018, 29, 1258-1272.	1.1	159
35	Sexual behaviour and extraâ€genital colonisation in women treated for recurrent <i>Candida</i> vulvoâ€vaginitis. Mycoses, 2018, 61, 857-860.	4.0	9
36	The ReCiDiF method to treat recurrent vulvovaginal candidosis: A friend with benefits. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, E5.	1.0	3

#	Article	IF	CITATIONS
37	Is multiple-site colonization with Candida spp. related to inadequate response to individualized fluconazole maintenance therapy in women with recurrent Candida vulvovaginitis?. Diagnostic Microbiology and Infectious Disease, 2018, 92, 226-229.	1.8	6
38	Bacterial vaginosis and inflammatory response showed association with severity of cervical neoplasia in HPVâ€positive women. Diagnostic Cytopathology, 2017, 45, 472-473.	1.0	9
39	Mycoplasma/Ureaplasma infection in pregnancy: to screen or not to screen. Journal of Perinatal Medicine, 2017, 45, 505-515.	1.4	80
40	Nonâ€response to fluconazole maintenance treatment (ReCiDiF regimen) for recurrent vulvovaginal candidosis is not related to impaired glucose metabolism. Mycoses, 2017, 60, 546-551.	4.0	10
41	Aerobic vaginitis: no longer a stranger. Research in Microbiology, 2017, 168, 845-858.	2.1	155
42	Women without vulvodynia can have a positive â€~Q-tip test': a cross sectional study. Journal of Psychosomatic Obstetrics and Gynaecology, 2017, 38, 256-259.	2.1	11
43	Deconstructing the genitourinary syndrome of menopause. International Urogynecology Journal, 2017, 28, 675-679.	1.4	29
44	Improvement of abnormal vaginal flora in Ugandan women by self-testing and short use of intravaginal antimicrobials. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 731-738.	2.9	6
45	Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 593-594.	2.9	2
46	Clinical Validation of a Test for the Diagnosis of Vaginitis. Obstetrics and Gynecology, 2017, 130, 912-912.	2.4	2
47	Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. Gynecologic and Obstetric Investigation, 2017, 82, 607-616.	1.6	7
48	2017 European guidelines for the management of genital herpes. International Journal of STD and AIDS, 2017, 28, 1366-1379.	1.1	91
49	Clinical evaluation of the NK3 receptor antagonist fezolinetant (a.k.a. ESN364) for the treatment of menopausal hot flashes. Maturitas, 2017, 103, 89-90.	2.4	10
50	Influence of contraceptive choice on vaginal bacterial and fungal microflora. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 43-48.	2.9	26
51	<i>Candida</i> vulvovaginitis: A store with a buttery and a show window. Mycoses, 2017, 60, 70-72.	4.0	23
52	Genital Tract Infections in an Isolated Community: 100 Women of the PrÃncipe Island. Infectious Diseases in Obstetrics and Gynecology, 2017, 2017, 1-6.	1.5	9
53	Distribution of Chlamydia trachomatis genotypes in neonatal conjunctivitis in Hungary. Journal of Medical Microbiology, 2017, 66, 915-918.	1.8	7
54	Bacterial vaginosis, aerobic vaginitis, vaginal inflammation and major Pap smear abnormalities. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 657-664.	2.9	50

#	Article	IF	CITATIONS
55	Diagnosis of aerobic vaginitis by quantitative real-time PCR. Archives of Gynecology and Obstetrics, 2016, 294, 109-114.	1.7	41
56	Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine. Obstetrics and Gynecology, 2016, 127, 213-221.	2.4	77
57	Screening for abnormal vaginal microflora by self-assessed vaginal pH does not enable detection of sexually transmitted infections in Ugandan women. Diagnostic Microbiology and Infectious Disease, 2016, 85, 227-230.	1.8	5
58	Utility of Microscopic Techniques and Quantitative Real-time Polymerase Chain Reaction for the Diagnosis of Vaginal Microflora Alterations. Journal of Lower Genital Tract Disease, 2015, 19, 124-128.	1.9	26
59	Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric, 2015, 18, 252-259.	2.4	38
60	Selecting Anti-Microbial Treatment of Aerobic Vaginitis. Current Infectious Disease Reports, 2015, 17, 477.	3.0	35
61	Effect of Short Training on Vaginal Fluid Microscopy (Wet Mount) Learning. Journal of Lower Genital Tract Disease, 2015, 19, 165-169.	1.9	18
62	Development of a Microarray-Based Tool To Characterize Vaginal Bacterial Fluctuations and Application to a Novel Antibiotic Treatment for Bacterial Vaginosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 2825-2834.	3.2	19
63	Vaginal microbiome and metabolome highlight specific signatures of bacterial vaginosis. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2367-2376.	2.9	116
64	Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2023-2028.	2.9	29
65	Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Medical Directors Association, 2015, 16, 740-747.	2.5	485
66	Cervicovaginal Levels of Proinflammatory Cytokines Are Increased During Chlamydial Infection in Bacterial Vaginosis But Not in Lactobacilli-Dominated Flora. Journal of Lower Genital Tract Disease, 2014, 18, 261-265.	1.9	17
67	Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. Vaccine, 2014, 32, 3694-3705.	3.8	20
68	Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Research and Treatment, 2014, 145, 371-379.	2.5	96
69	Treatment of bacterial vaginosis: what we have and what we miss. Expert Opinion on Pharmacotherapy, 2014, 15, 645-657.	1.8	68
70	Rifaximin Modulates the Vaginal Microbiome and Metabolome in Women Affected by Bacterial Vaginosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 3411-3420.	3.2	40
71	Anything Wrong With Conventional Wet Mount Microscopy?. Journal of Lower Genital Tract Disease, 2014, 18, E26-E27.	1.9	0
72	Composition of Vaginal Microflora in Relation to Vaginal pH and Wet Mount Diagnostic Tests in the First Trimester of Pregnancy. Proceedings of the Latvian Academy of Sciences, 2014, 67, 478-484.	0.1	0

#	Article	IF	CITATIONS
73	Assessing severity of pain in women with focal provoked vulvodynia: are von Frey filaments suitable devices?. Journal of reproductive medicine, The, 2014, 59, 134-8.	0.2	2
74	Impact of vaginal ascorbic acid on abnormal vaginal microflora. Archives of Gynecology and Obstetrics, 2013, 288, 1039-1044.	1.7	7
75	Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: outcomes of rifaximin treatment. Journal of Antimicrobial Chemotherapy, 2013, 68, 2648-2659.	3.0	19
76	A multicenter, doubleâ€blind, randomized, placeboâ€controlled study of rifaximin for the treatment of bacterial vaginosis. International Journal of Gynecology and Obstetrics, 2013, 120, 131-136.	2.3	18
77	Self-Sampling in the Diagnosis of Recurrent Vulvovaginal Candidosis. Journal of Lower Genital Tract Disease, 2013, 17, 187-192.	1.9	15
78	Increased Prevalence of Trichomonas vaginalis in Mid-Aged Women Is Linked to Sexual Activity and Not to Hormonal Changes. Journal of Lower Genital Tract Disease, 2013, 17, e31-e32.	1.9	4
79	Characterization of the Vaginal Micro- and Mycobiome in Asymptomatic Reproductive-Age Estonian Women. PLoS ONE, 2013, 8, e54379.	2.5	199
80	Association of Trichomonas vaginalis and Cytological Abnormalities of the Cervix in Low Risk Women. PLoS ONE, 2013, 8, e86266.	2.5	43
81	Cream With Cutaneous Fibroblast Lysate for the Treatment of Provoked Vestibulodynia. Journal of Lower Genital Tract Disease, 2012, 16, 427-436.	1.9	35
82	Correlation of Atopobium vaginae Amount With Bacterial Vaginosis Markers. Journal of Lower Genital Tract Disease, 2012, 16, 127-132.	1.9	27
83	Acceptance of self-testing for increased vaginal pH in different subsets of Ugandan women. International Journal of STD and AIDS, 2012, 23, 30-35.	1.1	7
84	Efficacy of Rifaximin Vaginal Tablets in Treatment of Bacterial Vaginosis: a Molecular Characterization of the Vaginal Microbiota. Antimicrobial Agents and Chemotherapy, 2012, 56, 4062-4070.	3.2	23
85	Exploring a Road Map to Counter Misconceptions About the Cervicovaginal Microbiome and Disease. Reproductive Sciences, 2012, 19, 1154-1162.	2.5	28
86	A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety. Gynecologic and Obstetric Investigation, 2012, 73, 8-15.	1.6	45
87	Characteristics of the pain observed in the focal vulvodynia syndrome (VVS). Medical Hypotheses, 2012, 78, 11-14.	1.5	22
88	Adaptive Changes in the Splenic Artery and Left Portal Vein in Fetal Growth Restriction. Journal of Ultrasound in Medicine, 2012, 31, 223-229.	1.7	1
89	Chlamydial infection in a high risk population: association with vaginal flora patterns. Archives of Gynecology and Obstetrics, 2012, 285, 1013-1018.	1.7	22
90	Simple posterior vestibuloplasty for central introital dyspareunia. Gynecological Surgery, 2012, 9, 297-302.	0.9	3

#	Article	IF	CITATIONS
91	Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device. Contraception, 2011, 83, 352-356.	1.5	35
92	Placental pathology in fetal growth restriction. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 155, 36-40.	1.1	109
93	Age of sexual debut and central introital dyspareunia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 90-92.	1.1	9
94	European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011. International Journal of STD and AIDS, 2011, 22, 421-429.	1.1	91
95	Self-elimination of risk factors for recurrent vaginal candidosis. Mycoses, 2011, 54, 39-45.	4.0	22
96	Factors related to elevated vaginal pH in the first trimester of pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 41-46.	2.8	26
97	The prevalence of bacterial vaginosis and aerobic vaginitis in young Finish women. Apmis, 2011, 119, 224-225.	2.0	2
98	Amniotic Fluid Interleukin-1 Beta and Interleukin-6, but not Interleukin-8 Correlate with Microbial Invasion of the Amniotic Cavity in Preterm Labor. American Journal of Reproductive Immunology, 2011, 65, 549-556.	1.2	84
99	Microscopic lesions of placenta and Doppler velocimetry related to fetal growth restriction. Archives of Gynecology and Obstetrics, 2011, 284, 1087-1093.	1.7	15
100	The effect of antifungal treatment on the vaginal flora of women with vulvo-vaginal yeast infection with or without bacterial vaginosis. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 59-63.	2.9	10
101	Interobserver Variability in Vaginal Fluid Wet Mount Microscopy Can Be Reduced by Precise Definition of Flora Types and Use of Phase Contrast. Journal of Lower Genital Tract Disease, 2011, 15, 331-332.	1.9	2
102	Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. Journal of the Turkish German Gynecology Association, 2011, 12, 239-246.	0.6	13
103	Diagnosis and Management of Bacterial Vaginosis and Other Types of Abnormal Vaginal Bacterial Flora: A Review. Obstetrical and Gynecological Survey, 2010, 65, 462-473.	0.4	85
104	Editorial. Gynecologic and Obstetric Investigation, 2010, 70, 221-223.	1.6	0
105	Epidemiology of <i>Trichomonas vaginalis</i> and Human Papillomavirus Infection Detected by Real-Time PCR in Flanders. Gynecologic and Obstetric Investigation, 2010, 70, 273-280.	1.6	49
106	Preventable Maternal Risk Factors and Association of Genital Infection with Fetal Growth Restriction. Gynecologic and Obstetric Investigation, 2010, 70, 291-298.	1.6	11
107	Pregnancy Loss Ascribable to Parvovirus B19/Erythrovirus Is Associated with a High Prevalence of Trisomy. Gynecologic and Obstetric Investigation, 2010, 70, 328-334.	1.6	3
108	Easiness of Use and Validity Testing of <i>VS-SENSE</i> Device for Detection of Abnormal Vaginal Flora and Bacterial Vaginosis. Infectious Diseases in Obstetrics and Gynecology, 2010, 2010, 1-7.	1.5	7

#	Article	IF	CITATIONS
109	Management of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness. Gynecologic and Obstetric Investigation, 2010, 70, 306-321.	1.6	72
110	Fetal growth restriction in Latvia. International Journal of Gynecology and Obstetrics, 2010, 111, 185-186.	2.3	6
111	Predicting Fetal Prognosis by Assessing Fetal and Maternal Blood Flow Patterns in Pregnancies with Fetal Growth Restriction. Acta Chirurgica Latviensis, 2010, 10, 42-47.	0.2	1
112	Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 1315-1324.	2.3	335
113	Change in knowledge of women about cervix cancer, human papilloma virus (HPV) and HPV vaccination due to introduction of HPV vaccines. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 145, 93-95.	1.1	36
114	Can vaginal pH be measured from the wet mount slide?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 146, 100-103.	1.1	2
115	Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium. Archives of Gynecology and Obstetrics, 2008, 277, 291-298.	1.7	60
116	Placental histological inflammation and reproductive tract infections in a low risk pregnant population in Latvia. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 360-365.	2.8	52
117	Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). American Journal of Obstetrics and Gynecology, 2008, 199, 613.e1-613.e9.	1.3	92
118	Mannoseâ€binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 1225-1231.	2.3	79
119	Non-cardiogenic lung edema in a woman treated with atosiban for preterm labor. Journal of Perinatal Medicine, 2008, 36, 455-7.	1.4	12
120	Efficacy of a Single Oral Dose of 200 mg Pramiconazole in Vulvovaginal Yeast Infections: An Exploratory Phase IIa Trial. Acta Dermato-Venereologica, 2008, 88, 462-466.	1.3	8
121	Dynamics of Vaginal Bacterial Communities in Women Developing Bacterial Vaginosis, Candidiasis, or No Infection, Analyzed by PCR-Denaturing Gradient Gel Electrophoresis and Real-Time PCR. Applied and Environmental Microbiology, 2007, 73, 5731-5741.	3.1	101
122	Comparison of two types of dipsticks to measure vaginal pH in clinical practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 134, 220-224.	1.1	21
123	Human chorionic gonadotropin (hCG) and prevention of breast cancer. Molecular and Cellular Endocrinology, 2007, 269, 93-98.	3.2	40
124	Definition and classification of abnormal vaginal flora. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2007, 21, 355-373.	2.8	176
125	The impact of social factors on attendance at antenatal care services and the subsequent effect on mothers' health, measured during the years of economic transition in Latvia. European Clinics in Obstetrics and Gynaecology, 2007, 3, 47-51.	0.4	3
126	Vulvar ulcers: a differential diagnosis between Behçet's disease and Lipschütz ulcus. European Clinics in Obstetrics and Gynaecology, 2007, 3, 59-62.	0.4	2

#	Article	IF	CITATIONS
127	Management of genital infections in pregnant women. Current Opinion in Infectious Diseases, 2006, 19, 55-61.	3.1	7
128	Prediction of recurrence after treatment for highâ€grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 1303-1307.	2.3	112
129	Aerobic vaginitis: Abnormal vaginal flora entity that is distinct from bacterial vaginosis. International Congress Series, 2005, 1279, 118-129.	0.2	17
130	Spontaneous midgestation abortion associated with Bacteroides fragilis: a case report. Infectious Diseases in Obstetrics and Gynecology, 2005, 13, 241-3.	1.5	1
131	Vaginal cytokines in normal pregnancy. American Journal of Obstetrics and Gynecology, 2003, 189, 1433-1438.	1.3	47
132	Impaired tolerance for glucose in women with recurrent vaginal candidiasis. American Journal of Obstetrics and Gynecology, 2002, 187, 989-993.	1.3	59
133	Lower genital tract infections in diabetic women. Current Infectious Disease Reports, 2002, 4, 536-539.	3.0	34
134	An international study of the interobserver variation between interpretations of vaginal smear criteria of bacterial vaginosis. Apmis, 2002, 110, 811-818.	2.0	47
135	Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109, 34-43.	2.3	390
136	We, specialists in vulvovaginitis. American Journal of Obstetrics and Gynecology, 2001, 184, 248.	1.3	9
137	WET SMEAR COMPARED WITH GRAM STAIN DIAGNOSIS IN ASYMPTOMATIC PREGNANT WOMEN. Obstetrics and Gynecology, 2001, 97, 482.	2.4	1
138	Lethal Sepsis Due to Traditional Healing. Infectious Diseases in Obstetrics and Gynecology, 2000, 8, 76-76.	1.5	0
139	Treatment of Sexually Transmitted Bacterial Diseases in Pregnant Women. Drugs, 2000, 59, 477-485.	10.9	33
140	Microscopy of the Bacterial Flora on Fresh Vaginal Smears. Infectious Diseases in Obstetrics and Gynecology, 1999, 7, 126-127.	1.5	22
141	Apparent Failure of One Injection of Benzathine Penicillin G for Syphilis During Pregnancy in Human Immunodeficiency Virus-Seronegative African Women. Sexually Transmitted Diseases, 1997, 24, 94-101.	1.7	48
142	Rapid Antigen Tests for Neisseria gonorrhoeae and Chlamydia trachomatis Are Not Accurate for Screening Women with Disturbed Vaginal Lactobacillary Flora. Scandinavian Journal of Infectious Diseases, 1996, 28, 559-562.	1.5	7
143	Lactobacilli in Papanicolaou Smears, Genital Infections, and Pregnancy. American Journal of Perinatology, 1993, 10, 358-361.	1.4	44
144	Scanning electron microscopic study of microvascular anastomoses on irradiated vessels: Long-term effect of irradiation. Microsurgery, 1986, 7, 156-157.	1.3	19